IL97909A0 - Anti-tnf antibodies for the treatment of ischaemias and their consequences - Google Patents

Anti-tnf antibodies for the treatment of ischaemias and their consequences

Info

Publication number
IL97909A0
IL97909A0 IL97909A IL9790991A IL97909A0 IL 97909 A0 IL97909 A0 IL 97909A0 IL 97909 A IL97909 A IL 97909A IL 9790991 A IL9790991 A IL 9790991A IL 97909 A0 IL97909 A0 IL 97909A0
Authority
IL
Israel
Prior art keywords
ischaemias
consequences
treatment
tnf antibodies
tnf
Prior art date
Application number
IL97909A
Other versions
IL97909A (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL97909A0 publication Critical patent/IL97909A0/en
Publication of IL97909A publication Critical patent/IL97909A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of anti-TNF antibodies to treat ischaemic and its sequelae, is claimed, especially when the ischaemia is an infarct or results from transplantation.
IL97909A 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences IL97909A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (en) 1990-04-25 1990-11-27 Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants

Publications (2)

Publication Number Publication Date
IL97909A0 true IL97909A0 (en) 1992-06-21
IL97909A IL97909A (en) 1997-09-30

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97909A IL97909A (en) 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Country Status (7)

Country Link
EP (1) EP0453898B1 (en)
JP (1) JPH04364133A (en)
AT (1) ATE123226T1 (en)
DE (2) DE4037604A1 (en)
DK (1) DK0453898T3 (en)
ES (1) ES2073059T3 (en)
IL (1) IL97909A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4307508A1 (en) * 1993-03-10 1994-09-15 Knoll Ag Use of anti-TNF antibodies as a medicine in the treatment of heart failure (heart muscle weakness)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (en) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
JP2638652B2 (en) * 1988-07-18 1997-08-06 カイロン・コーポレーション Monoclonal antibody reacting with cachectin

Also Published As

Publication number Publication date
ES2073059T3 (en) 1995-08-01
DK0453898T3 (en) 1995-10-09
JPH04364133A (en) 1992-12-16
ATE123226T1 (en) 1995-06-15
EP0453898A3 (en) 1991-12-18
DE4037604A1 (en) 1991-10-31
DE59105609D1 (en) 1995-07-06
EP0453898B1 (en) 1995-05-31
EP0453898A2 (en) 1991-10-30
IL97909A (en) 1997-09-30

Similar Documents

Publication Publication Date Title
IL97909A0 (en) Anti-tnf antibodies for the treatment of ischaemias and their consequences
EP0865293A4 (en) Blockade of t lymphocyte down-regulation associated with ctla-4 signaling
ATE439137T1 (en) TREATMENT OF HEMATOLOGICAL DISORDERS
GR3029683T3 (en) CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS.
HK1048831A1 (en) Human ctla-4 antibodies and their uses
ES2099158T3 (en) TREATMENT OF REJECTION OF TRANSPLANTS OR AUTOIMMUNE DISEASES AND COMPLEX OF THE GENERAL FORMULA X-PRO-Y-BOROPRO ASSOCIATED WITH THE SAME.
DE69316948T2 (en) Soluble ligands for CD40
NO982062L (en) Humanized antibodies to human gp39, compositions containing them, and therapeutic use thereof
EP0552296A4 (en) Mouse monoclonal antibodies
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
NZ306443A (en) Vaccine for treating chlamydia comprising momp protein from chlamydia in conjunction with 3d-mpl and qs21
EP0647138A4 (en) Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same.
AU7275891A (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
TW223019B (en)
WO2020092969A8 (en) Monoclonal antibodies to eltd1 and uses thereof
FR2059561A1 (en) Anti aphthic vaccine
IT1318393B1 (en) Protein material for the diagnosis, the prophylaxis and the treatment of human cytomegalovirus infections
IT1158511B (en) Skin treatment compn contng biogenic
UA5542A1 (en) Device for bio-material freezing
MX9400210A (en) TREATMENT OF VIRAL INFECTIONS.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees